Improving the therapeutic index when using Myocet™ in the treatment of metastatic breast cancer

Breast

Volumn 10, Issue SUPPL. 2, 2001, Pages 16-21

  Batist, G ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CITRIC ACID; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; LIPOSOME; METHOTREXATE; MITOXANTRONE; NAVELBINE; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL OBSERVATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; HUMAN; INFECTION; LONG TERM CARE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL SUPPORT;

EID: 0034989283     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(01)80003-5     Document Type: Article

References (39)

1. Progress in chemotherapy for metastatic breast cancer
2. Survival from first recurrence: Relative importance of prognostic factors in 1015 breast cancer patients
3. Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies?
4. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
5. Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer
6. Ten-year follow-up study of premenopausal women with metastatic breast cancer
7. Chemotherapeutic approaches to advanced breast cancer
8. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens
9. Anthracycline antibiotics in cancer therapy. Focus on drug resistance
10. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
11. Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis
12. Metastatic breast cancer: Prolonged complete remission or possible cure with chemotherapy
13. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies
14. Diminished efficacy by reducing duration of CEF from 18 to 6 months in the treatment of metastatic breast cancer
15. Quality of life in patients with breast cancer randomised to high dose chemotherapy with bone marrow support vs. intermediate dose chemotherapy
16. Quality of life in a randomised adjuvant breast carcinoma study with standard versus high-dose chemotherapy
17. The importance of dose intensity in chemotherapy of metastatic breast cancer
18. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma
19. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: Results of a randomized trial
20. A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer
21. Dose response relationship with epirubicin as first line chemotherapy for advanced breast cancer. A randomized trial
22. Combination chemotherapy and adriamycin in patients with advanced breast cancer
23. Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomised trial of two dosage schedules
24. Antineoplastic drugs in 1990: A review
25. Doxorubicin (adriamycin) cardiomyopathy
26. Doxorubicin cardiotoxicity
27. Doxorubicin-induced cardiomyopathy
28. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity
29. Anthracycline-induced cardiotoxicity
30. Risk factors for doxorubicin-induced congestive heart failure
31. The management of locally advanced breast cancer
32. Relation of tumour size, lymph node status and survival in 24740 breast cancer cases
33. Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer
34. Adjuvant therapy for early stage breast cancer
35. Liposomal doxorubicin
36. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99) given intraperitoneally to dogs
37. Reduced cardiotoxicity and preserved antitumour efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicentre cancer
38. Phase III study of TLC D-99 (liposome-encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast carcinoma (MBC)
39. Improved therapeutic index of TLC D-99 (liposome-encapsulated doxorubicin) compared to free doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin